RecruitingPregnant IndividualsAneuploidyDown Syndrome (Trisomy 21)
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
Eligible age
All ages
Accepts
Women
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic and clinical diagnosis of the resulting neonate. This is a prospective study of pregnant individuals.
Sponsor: BillionToOne Inc.
You may qualify if…
- ✓ pregnant individuals between 10 and 20 weeks of gestation
- ✓ singleton gestation
You may not qualify if…
- ✕ \- active cancer
Where it's recruiting
Source: ClinicalTrials.gov · NCT07643896 · last updated 2026-06-12